Elevation of glutathione as a therapeutic strategy in Alzheimer disease

被引:285
作者
Pocernich, Chava B. [1 ,2 ]
Butterfield, D. Allan [1 ,2 ,3 ]
机构
[1] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA
[2] Univ Kentucky, Ctr Membrane Sci, Lexington, KY 40506 USA
[3] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2012年 / 1822卷 / 05期
关键词
Alzheimer disease (AD); Mild cognitive impairment (MCI); Amyloid beta-peptide; Glutathione (GSH); N-acetylcysteine (NAC); gamma-Glutamylcysteine ethyl ester; MILD COGNITIVE IMPAIRMENT; GLUTAMYLCYSTEINE ETHYL-ESTER; ACETYL-L-CYSTEINE; OXIDATIVELY MODIFIED PROTEINS; REDOX PROTEOMICS IDENTIFICATION; IN-VIVO; LIPID-PEROXIDATION; SYNAPTOSOMAL MEMBRANES; CONTROLLED-TRIAL; MESSENGER-RNA;
D O I
10.1016/j.bbadis.2011.10.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Oxidative stress has been associated with the onset and progression of mild cognitive impairment (MCI) and Alzheimer disease (AD). AD and MCI brain and plasma display extensive oxidative stress as indexed by protein oxidation, lipid peroxidation, free radical formation, DNA oxidation, and decreased antioxidants. The most abundant endogenous antioxidant, glutathione, plays a significant role in combating oxidative stress. The ratio of oxidized to reduced glutathione is utilized as a measure of intensity of oxidative stress. Antioxidants have long been considered as an approach to slow down AD progression. In this review, we focus on the elevation on glutathione through N-acetyl-cysteine (NAC) and gamma-glutamylcysteine ethyl ester (GCEE) as a potential therapeutic approach for Alzheimer disease. This article is part of a Special Issue entitled: Antioxidants and Antioxidant Treatment in Disease. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:625 / 630
页数:6
相关论文
共 85 条
[1]  
Abramov AY, 2003, J NEUROSCI, V23, P5088
[2]   Controlled trial of N-acetyleysteine for patients with probable Alzheimer's disease [J].
Adair, JC ;
Knoefel, JE ;
Morgan, N .
NEUROLOGY, 2001, 57 (08) :1515-1517
[3]   Preclinical Alzheimer disease: Brain oxidative stress, Aβ peptide and proteomics [J].
Aluise, Christopher D. ;
Robinson, Rena A. Sowell ;
Beckett, Tina L. ;
Murphy, M. Paul ;
Cai, Jian ;
Pierce, William M. ;
Markesbery, William R. ;
Butterfield, D. Allan .
NEUROBIOLOGY OF DISEASE, 2010, 39 (02) :221-228
[4]   TRANSPORT AND DIRECT UTILIZATION OF GAMMA-GLUTAMYLCYST(E)INE FOR GLUTATHIONE SYNTHESIS [J].
ANDERSON, ME ;
MEISTER, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (03) :707-711
[5]   Glutathione therapy: From prodrugs to genes [J].
Anderson, ME ;
Luo, JL .
SEMINARS IN LIVER DISEASE, 1998, 18 (04) :415-424
[6]  
Baldeiras I, 2008, J ALZHEIMERS DIS, V15, P117
[7]   Oxidative Damage and Progression to Alzheimer's Disease in Patients with Mild Cognitive Impairment [J].
Baldeiras, Ines ;
Santana, Isabel ;
Proenca, Maria Teresa ;
Garrucho, Maria Helena ;
Pascoal, Rui ;
Rodrigues, Ana ;
Duro, Diana ;
Oliveira, Catarina Resende .
JOURNAL OF ALZHEIMERS DISEASE, 2010, 21 (04) :1165-1177
[8]   Is glutathione an important neuroprotective effector molecule against amyloid beta toxicity? (Reprinted from Thiol Metabolism and Redox Regulation of Cellular Functions) [J].
Barber, VS ;
Griffiths, HR .
BIOFACTORS, 2003, 17 (1-4) :215-228
[9]   γ-glutamylcysteine ethyl ester protection of proteins from Aβ(1-42)-mediated oxidative stress in neuronal cell culture:: A proteomics approach [J].
Boyd-Kimball, D ;
Sultana, R ;
Poon, HF ;
Mohmmad-Abdul, H ;
Lynn, BC ;
Klein, JB ;
Butterfield, DA .
JOURNAL OF NEUROSCIENCE RESEARCH, 2005, 79 (05) :707-713
[10]   γ-glutamylcysteine ethyl ester-induced up-regulation of glutathione protects neurons against Aβ(1-42)-mediated oxidative stress and neurotoxicity:: Implications for Alzheimer's disease [J].
Boyd-Kimball, D ;
Sultana, R ;
Abdul, HM ;
Butterfield, DA .
JOURNAL OF NEUROSCIENCE RESEARCH, 2005, 79 (05) :700-706